Reivindicaciones

1. Use of an antibody which binds to a CCR7 receptor and is effective for killing tumour cells expressing said CCR7 receptor in the manufacture of a pharmaceutical composition for killing tumour cells expressing a CCR7 receptor. 2. Use according to claim 1, wherein said tumour cells are chronic lymphocytic leukaemia (CLL) cells or Mantle Cell Lymphoma (MCL) cells. 3. Use according to claim 1 or 2, wherein the antibody which binds to a CCR7 receptor is used in combination with an additional therapeutically active compound, wherein said additional therapeutically active compound is selected from the group consisting of a cytokine, an analgesic agent, an immunosuppressive agent and a chemotherapeutic agent. 4. An in vitro method for killing tumour cells expressing a CCR7 receptor which comprises contacting said cells with an antibody which binds to said CCR7 receptor and is effective for killing tumour cells expressing said CCR7 receptor. 5. Method according to claim 4, wherein said tumour cells are chronic lymphocytic leukaemia (CLL) cells or Mantle Cell Lymphoma (MCL) cells. 6. A method for identifying a compound for killing tumour cells expressing a CCR7 receptor which comprises a) contacting a cell expressing a CCR7 receptor with a candidate compound coupled to an anti-CCR7 antibody and b) determining whether said candidate compound kills said cells expressing a CCR7 receptor, wherein a compound that kills said cells expressing a CCR7 receptor, is a compound potentially useful for killing tumour cells. 7. Method according to claim 6, wherein said cells are chronic lymphocytic leukaemia (CLL) cells or Mantle Cell Lymphoma (MCL) cells. 44 8. Use of an antibody which binds to a CCR7 receptor and is effective for killing tumour cells expressing said CCR7 receptor for killing tumour cells expressing said CCR7 receptor. 9. Use according to claim 8, wherein said cells are chronic lymphocytic leukaemia (CLL) cells or Mantle Cell Lymphoma (MCL) cells.